Autoimmune drug gets easier shot? study tests new injection device

NCT ID NCT06293365

Summary

This study is testing if a new, single auto-injector pen delivers the same amount of the drug ianalumab into the body as two separate pre-filled syringes. It involves 155 adults with rheumatoid arthritis, lupus, or Sjögren's disease. The main goal is to see if the drug levels in the blood are comparable between the two methods, while also checking safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Advanced Medical Research

    La Palma, California, 90623, United States

  • Advanced Rheumatology of Houston

    Spring, Texas, 77382, United States

  • Ahmed Arif Medical Research Center

    Grand Blanc, Michigan, 48439, United States

  • Altoona Center for Clin Res

    Duncansville, Pennsylvania, 16635, United States

  • Conquest Research

    Winter Park, Florida, 32789, United States

  • Indiana Univ School of Dentistry

    Indianapolis, Indiana, 46202, United States

  • Novartis Investigative Site

    Quilmes, Buenos Aires, 1878, Argentina

  • Novartis Investigative Site

    San Miguel de Tucumán, Tucumán Province, T4000DPK, Argentina

  • Novartis Investigative Site

    Buenos Aires, 1646, Argentina

  • Novartis Investigative Site

    Buenos Aires, C1055AAF, Argentina

  • Novartis Investigative Site

    Hamilton, Ontario, L8N 3Z5, Canada

  • Novartis Investigative Site

    Toronto, Ontario, M5T 2S8, Canada

  • Novartis Investigative Site

    Rimouski, Quebec, G5L 5T1, Canada

  • Novartis Investigative Site

    Trois-Rivières, Quebec, G9A 3Y2, Canada

  • Novartis Investigative Site

    Brno, 638 00, Czechia

  • Novartis Investigative Site

    Prague, 128 00, Czechia

  • Novartis Investigative Site

    Uherské Hradiště, 686 01, Czechia

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    Budapest, 1027, Hungary

  • Novartis Investigative Site

    Budapest, 1036, Hungary

  • Novartis Investigative Site

    Salerno, SA, 84131, Italy

  • Novartis Investigative Site

    Krakow, 30-002, Poland

  • Novartis Investigative Site

    Lublin, 20-607, Poland

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, 15706, Spain

  • Novartis Investigative Site

    A Coruña, 15006, Spain

  • Novartis Investigative Site

    Madrid, 28034, Spain

  • Novel Research LLC

    Bellaire, Texas, 77401, United States

  • Ochsner Health System

    Baton Rouge, Louisiana, 70809, United States

  • Paramount Med Rsrch and Consult LLC

    Middleburg Heights, Ohio, 44130, United States

  • Parris and Associates Rheumatology

    Lawrenceville, Georgia, 30044, United States

  • Pinnacle Research Group Llc

    Anniston, Alabama, 36207, United States

  • Providence Medical Foundation

    Fullerton, California, 92835, United States

  • RAO Research LLC

    Oklahoma City, Oklahoma, 73116, United States

  • Shelby Research LLC

    Memphis, Tennessee, 38119, United States

  • Southwest Rheum Rsrch LLC

    Mesquite, Texas, 75150, United States

  • Uni of Texas Health Science Center

    San Antonio, Texas, 78229, United States

  • West Tennessee Research Institute

    Jackson, Tennessee, 38305, United States

Conditions

Explore the condition pages connected to this study.